IP Library Granted Patent US 12,351,799
Granted Patent B2
US 12,351,799 · App. 18/970,552 · Granted Jul 8, 2025

S. pyogenes CAS9 mutant genes and polypeptides encoded by same

Inventors: Christopher Anthony Vakulskas (North Liberty, IA); Michael Allen Collingwood (North Liberty, IA); Garrett Richard Rettig (Coralville, IA); Mark Aaron Behlke (Coralville, IA)
Assignee: INTEGRATED DNA TECHNOLOGIES, INC.
C12N15/11C12N9/22C12N15/902C12N15/113C12N2310/20C12N2800/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,351,799
App. No.
18/970,552
Granted
Jul 8, 2025
Kind
B2
Abstract

This invention pertains to mutant Cas9 nucleic acids and proteins for use in CRISPR/Cas endonuclease systems, and their methods of use. In particular, the invention pertains to an isolated mutant Cas9 protein, wherein the isolated mutant Cas9 protein is active in a CRISPR/Cas endonuclease system, wherein the CRISPR/Cas endonuclease system displays reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system. The invention also includes isolated nucleic acids encoding mutant Cas9 proteins, ribonucleoprotein complexes and CRSPR/Cas endonuclease systems having mutant Cas9 proteins that display reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system.

Claims (9)

1. An isolated mutant Cas9 protein, comprising a single R691A substitution relative to the wild-type Cas9 amino acid sequence of SEQ ID NO: 5.

2. The isolated mutant Cas9 protein of claim 1 , further comprising at least one nuclear localization signal.

3. The isolated mutant Cas9 protein of claim 1 , wherein the isolated mutant Cas9 protein is Streptococcus pyogenes mutant Cas9 protein.

4. The isolated mutant Cas9 protein of claim 1 , wherein the isolated mutant Cas9 protein is a clustered regularly interspersed short palindromic repeats/CRISPR associated (CRISPR/Cas) endonuclease system protein.

5. The isolated mutant Cas9 protein of claim 4 , wherein the isolated mutant Cas9 protein is active in the CRISPR/Cas endonuclease system, and wherein the CRISPR/Cas endonuclease system displays reduced off-target editing activity and maintains on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system having the wild-type Cas9 protein of SEQ ID NO: 5.

6. The isolated mutant Cas9 protein of claim 1 , wherein the isolated mutant Cas9 protein comprises the amino acid sequence of SEQ ID NO: 7.

7. The isolated mutant Cas9 protein of claim 1 , wherein the isolated mutant Cas9 protein comprises the amino acid sequence of SEQ ID NO: 8.

8. An isolated nucleic acid encoding the isolated mutant Cas9 protein of claim 1 , wherein the isolated nucleic acid comprises the nucleic acid sequence of SEQ ID NO: 3.

9. An isolated nucleic acid encoding the isolated mutant Cas9 protein of claim 1 , wherein the isolated nucleic acid comprises the nucleic acid sequence of SEQ ID NO: 4.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2025
From: VAKULSKAS, CHRISTOPHER ANTHONY; COLLINGWOOD, MICHAEL ALLEN; RETTIG, GARRETT RICHARD; BEHLKE, MARK AARON
To: INTEGRATED DNA TECHNOLOGIES, INC.
Reel/Frame 071044/0344 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2025
From: VAKULSKAS, CHRISTOPHER ANTHONY; COLLINGWOOD, MICHAEL ALLEN; RETTIG, GARRETT RICHARD; BEHLKE, MARK AARON
To: INTEGRATED DNA TECHNOLOGIES, INC.
Reel/Frame 070132/0914 →
Continuity (5)
Continuation 17870190 · Jul 21, 2022
Continuation 16931889 · Jul 17, 2020
Division 15729491 · Oct 10, 2017
Provisional Application 62405601 · Oct 7, 2016
Related Publication 20250109395A1 · Apr 3, 2025
References Cited (50)
US 5672695A · Eckstein et al. · 1997 [cited by applicant]
US 6248878B1 · Matulic-Adamic et al. · 2001 [cited by applicant]
US 8697359B1 · Zhang · 2014 [cited by applicant]
US 9512446B1 · Joung et al. · 2016 [cited by applicant]
US 9840702B2 · Collingwood et al. · 2017 [cited by applicant]
US 10369232B2 · Chivukula et al. · 2019 [cited by applicant]
US 10717978B2 · Vakulskas et al. · 2020 [cited by applicant]
US 11427818B2 · Vakulskas et al. · 2022 [cited by applicant]
US 20140273226A1 · Wu et al. · 2014 [cited by applicant]
US 20140273232A1 · Zhang et al. · 2014 [cited by applicant]
US 20140295557A1 · Joung et al. · 2014 [cited by applicant]
US 20150059010A1 · Cigan et al. · 2015 [cited by applicant]
US 20150073041A1 · Saltzman et al. · 2015 [cited by applicant]
US 20160017396A1 · Cann et al. · 2016 [cited by applicant]
US 20160024524A1 · Joung et al. · 2016 [cited by applicant]
US 20160208241A1 · Tsai et al. · 2016 [cited by applicant]
US 20160208243A1 · Zhang et al. · 2016 [cited by applicant]
US 20160215300A1 · May et al. · 2016 [cited by applicant]
US 20160289675A1 · Ryan et al. · 2016 [cited by applicant]
US 20160312198A1 · Joung et al. · 2016 [cited by applicant]
US 20160362667A1 · Donohoue et al. · 2016 [cited by applicant]
US 20180100148A1 · Vakulskas et al. · 2018 [cited by applicant]
US 20190010471A1 · Zhang et al. · 2019 [cited by applicant]
US 20200149020A1 · Cereseto et al. · 2020 [cited by applicant]
US 20200149022A1 · Kim et al. · 2020 [cited by applicant]
CN 106244591A · 2016 [cited by applicant]
WO 2014065596A1 · 2014 [cited by applicant]
WO 2014093622A2 · 2014 [cited by applicant]
WO 2014124226A1 · 2014 [cited by applicant]
WO 2014144592A2 · 2014 [cited by applicant]
WO 2016080097A1 · 2016 [cited by applicant]
WO 2016089433A1 · 2016 [cited by applicant]
WO 2016115179A1 · 2016 [cited by applicant]
WO 2016161207A1 · 2016 [cited by applicant]
WO 2016164356A1 · 2016 [cited by applicant]
WO 2016205613A1 · 2016 [cited by applicant]
WO 2017040348A1 · 2017 [cited by applicant]
WO 2017147432A1 · 2017 [cited by applicant]
WO 2017184799A1 · 2017 [cited by applicant]
Siloto et al., “Site saturation mutagenesis: Methods and applications in protein engineering”, Biocatalysis and Agricultural Biotechnology, vol. 1, (2012), pp. 181-189. [cited by examiner]
Vakulskas et al., “A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells”, Nature Medicine, 2018, vol. 24, pp. 1216-1224. [cited by examiner]
Airaksinen et al., “Modified Base Compositions at Degenerate Positions of a Mutagenic Oligonucleotide Enhance Randomness in Site-Saturation Mutagenesis”, Nucleic Acids Research, 1998, vol. 26, No. 2, pp. 576-581. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2018/029662 dated Apr. 14, 2020. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2017/055952 dated Apr. 9, 2019. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2017/055952 dated Apr. 6, 2018. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2018/029662 dated Aug. 13, 2018. [cited by applicant]
Kleinstiver, B. et al., “High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects”, Nature, vol. 529, No. 8698, Jan. 28, 2016. [cited by applicant]
Kleinstiver, B.P. et al., “Engineered CRISPR-Cas9 nucleases with altered PAM specificities” Nature, vol. 523, No. 7561, Jun. 22, 2015. [cited by applicant]
Office Action for South Korean Patent Application No. 10-2023-7040263 issued on Dec. 13, 2024 (includes English language translation). [cited by applicant]
Slaymaker , I. et al., “Rationally engineered Cas9 nucleases with improved specificity”, Science, American Association For The Advancement of Science, vol. 351, No. 6258, Jan. 1, 2016. [cited by applicant]